# A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine

> **NCT00741234** · PHASE1 · COMPLETED · sponsor: **S*BIO** · enrollment: 85 (actual)

## Conditions studied

- Solid Tumors
- Hematologic Malignancies
- Myelodysplastic Syndrome

## Interventions

- **DRUG:** SB939
- **DRUG:** Azacitidine

## Key facts

- **NCT ID:** NCT00741234
- **Lead sponsor:** S*BIO
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** 2012-03
- **Final completion:** 2012-03
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2012-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00741234

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00741234, "A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00741234. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*